Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study
Loriot Y, Ouatas T, Holtkamp G, Baron B, Heeringa M, Baskin-Bey E, James N, Omlin A, Molife R, Van den Brande J, Jones R, Fizazi K, de Bono J. Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs 2014; 32:995-1004.
27.04.2014
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study
27.04.2014
Invest New Drugs 2014; 32:995-1004
Loriot Yohann, Ouatas Taoufik, Holtkamp Gertjan M, Baron Benoit, Heeringa Marten, Baskin-Bey Edwina, James Nicholas D, Omlin Aurelius, Molife Rhoda L, Van den Brande Jan, Jones Robert J, Fizazi Karim, de Bono Johann S
Weiter
